JP2023548429A - パーキンソン病、特にｌ－ｄｏｐａ誘発性ジスキネジアのための医薬品に対する感作の予防または軽減における使用のための［２－（３－フルオロ－５－メタンスルホニルフェノキシ）エチル］（プロピル）アミン（メスドペタム） - Google Patents

パーキンソン病、特にｌ－ｄｏｐａ誘発性ジスキネジアのための医薬品に対する感作の予防または軽減における使用のための［２－（３－フルオロ－５－メタンスルホニルフェノキシ）エチル］（プロピル）アミン（メスドペタム） Download PDF

Info

Publication number
JP2023548429A
JP2023548429A JP2023550714A JP2023550714A JP2023548429A JP 2023548429 A JP2023548429 A JP 2023548429A JP 2023550714 A JP2023550714 A JP 2023550714A JP 2023550714 A JP2023550714 A JP 2023550714A JP 2023548429 A JP2023548429 A JP 2023548429A
Authority
JP
Japan
Prior art keywords
formula
compound
parkinson
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2023550714A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548429A5 (https=
JPWO2022101227A5 (https=
Inventor
スサンナ・ホルム・ウォーターズ
ヨアキム・ミッケル・テドロフ
ペル・スヴェニングソン
Original Assignee
インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー
アイアールエル７９０アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー, アイアールエル７９０アーベー filed Critical インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー
Publication of JP2023548429A publication Critical patent/JP2023548429A/ja
Publication of JP2023548429A5 publication Critical patent/JP2023548429A5/ja
Publication of JPWO2022101227A5 publication Critical patent/JPWO2022101227A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023550714A 2020-11-10 2021-11-09 パーキンソン病、特にｌ－ｄｏｐａ誘発性ジスキネジアのための医薬品に対する感作の予防または軽減における使用のための［２－（３－フルオロ－５－メタンスルホニルフェノキシ）エチル］（プロピル）アミン（メスドペタム） Abandoned JP2023548429A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20206645 2020-11-10
EP20206645.2 2020-11-10
PCT/EP2021/081162 WO2022101227A1 (en) 2020-11-10 2021-11-09 [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine (mesdopetam) for use in the prevention or reduction of sensitization to a pharmaceutical drug for parkinson's disease, in particular l-dopa induced dyskinesias

Publications (3)

Publication Number Publication Date
JP2023548429A true JP2023548429A (ja) 2023-11-16
JP2023548429A5 JP2023548429A5 (https=) 2024-11-18
JPWO2022101227A5 JPWO2022101227A5 (https=) 2024-11-18

Family

ID=73288427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023550714A Abandoned JP2023548429A (ja) 2020-11-10 2021-11-09 パーキンソン病、特にｌ－ｄｏｐａ誘発性ジスキネジアのための医薬品に対する感作の予防または軽減における使用のための［２－（３－フルオロ－５－メタンスルホニルフェノキシ）エチル］（プロピル）アミン（メスドペタム）

Country Status (10)

Country Link
US (2) US20220168242A1 (https=)
EP (1) EP4243801A1 (https=)
JP (1) JP2023548429A (https=)
KR (1) KR20230106659A (https=)
CN (1) CN116685314A (https=)
AR (1) AR124036A1 (https=)
AU (1) AU2021378472A1 (https=)
CA (1) CA3198266A1 (https=)
TW (1) TW202233169A (https=)
WO (1) WO2022101227A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024062344A1 (en) * 2022-09-21 2024-03-28 Assia Chemical Industries Ltd. Solid state forms of mesdopetam and salts therof
GB202312055D0 (en) 2023-08-07 2023-09-20 Ipsen Biopharm Ltd Pharmaceutical compositions
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080036957A (ko) 2005-06-23 2008-04-29 아스트라제네카 아베 위장 질환 치료용 뉴로키닌 수용체 길항제로서의 신규한아제티딘 유도체
CN103347517B (zh) * 2010-08-11 2018-10-02 德雷克塞尔大学 治疗帕金森病中运动障碍的d3多巴胺受体激动剂
EP2699543B1 (en) 2011-04-19 2016-03-02 Integrative Research Laboratories Sweden AB Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission
EP2858649B1 (en) * 2012-06-11 2019-10-23 Psychogenics Inc. Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
ES2869981T3 (es) * 2015-05-26 2021-10-26 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composiciones para su uso en el tratamiento de la enfermedad de parkinson y trastornos relacionados
WO2020110128A1 (en) * 2018-11-29 2020-06-04 Prilenia Neurotherapeutics Ltd. Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia
FI3976581T3 (fi) * 2019-05-24 2024-01-31 Irl 790 Ab [2-(3-fluori-5-metaani-sulfonyylifenoksi)etyyli](propyli)amiinin viinihapposuolat

Also Published As

Publication number Publication date
AR124036A1 (es) 2023-02-08
CA3198266A1 (en) 2022-05-19
AU2021378472A1 (en) 2023-06-15
TW202233169A (zh) 2022-09-01
US20220168242A1 (en) 2022-06-02
CN116685314A (zh) 2023-09-01
WO2022101227A1 (en) 2022-05-19
KR20230106659A (ko) 2023-07-13
US20240148674A1 (en) 2024-05-09
EP4243801A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
US20240148674A1 (en) Pharmaceutically acceptable salts of mesdopetam and uses thereof
CN101784273B (zh) (2s，3r)‑n‑(2‑((3‑吡啶基)甲基)‑1‑氮杂双环[2.2.2]辛‑3‑基)苯并呋喃‑2‑甲酰胺、其新的盐形式和用法
CN113853369B (zh) [2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺的药学上可接受的盐及其用途
RU2624446C9 (ru) Трициклические соединения, композиции, содержащие указанные соединения, и их применения
US10537569B2 (en) Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same
AU2017314560B2 (en) Crystals of cyclic amine derivative and pharmaceutical use thereof
EP3359148A1 (en) Combination of deuterated levodopa with carbidopa and opicapone for the treatment of parkinson`s disease
KR20240058807A (ko) 펠루비프로펜 및 트라마돌의 이온결합 화합물, 이를 포함하는 조성물, 및 이의 제조 방법
HK40092836A (zh) 用於预防或减轻对用於帕金森病、特别是l-dopa诱导的运动障碍的药学药物的致敏的[2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺(美多培坦)
CA2942117A1 (en) Pharmaceutical composition for the treatment of parkinson&#39;s disease
CN103570669B (zh) 脑靶向o-去甲基文拉法辛酚酯类前药及制备方法和用途
US3891768A (en) Treatment of Parkinson{3 s disease
HK40063249B (zh) [2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺的药学上可接受的盐及其用途
WO2010032731A1 (ja) 結晶態様のベンゾイミダゾール化合物又はその塩
HK40063249A (en) Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof
EP2340818A1 (en) Co-crystals of venlafaxine and celecoxib
CN113801120A (zh) Mdm2抑制剂的微悬浮液以及治疗应用
EA047399B1 (ru) Фармацевтически приемлемые соли [2-(3-фтор-5-метансульфонилфенокси)этил](пропил)амина и их применение
US20150313891A1 (en) Neuronal nicotinic agonists and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241108

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20250820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250821